DNTH Dianthus Therapeutics, Inc. /DE/

8-K Current Report

Filed: March 12, 2026

Health Care

Pharmaceutical Preparations

Dianthus Therapeutics, Inc. /DE/ Overview

Dianthus Therapeutics, Inc. /DE/ (DNTH) 8-K current report filed with SEC EDGAR on March 12, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
1 item

Item 1.01: Entry into a Material Definitive Agreement

AI Filing Analysis
8-K

Item 1.01 · Entry into a Material Definitive Agreement

• Offering priced at $81.00/share; 7.31M shares + 402K pre-funded warrants issued, with full 1.16M share overallotment exercised next day
• Net proceeds ~$673.5M after underwriting discounts and offering expenses

+3 more insights

Other Dianthus Therapeutics, Inc. /DE/ 8-K Filings

8-K Mar 9, 2026

Get deeper insights on Dianthus Therapeutics, Inc. /DE/

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.